Delusional.
I can’t believe you are again pushing the “maybe MSB did not accept Novartis’s money” spiel.
Firstly, msb are desperate for a partner and the cash they will need to go forward. Secondly msb said they have no idea why Novartis didn’t want to proceed. Thirdly, Novartis said they were not proceeding because of the data.
If it was the case they couldn’t cut a deal, I’d be pretty sure msb would have said that’s the reason … sure beats the poor data reason that was communicated.
As for your confident prediction that Novartis just wanted to look “under the hood” well, if msb have patients then all the IP is public and set out in the patient. That’s the whole idea.
As we have seen, partnership agreements don’t grow on trees. The notion that msb wouldn’t proceed is fancy.
MSB 2022 - The road to commercialisation, page-11
-
- There are more pages in this discussion • 1,518 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 94461 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 61151 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |